A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRX) Administered to Adults
With Familial Chylomicronemia Syndrome (FCS) Previously Treated With Volanesorsen
Research Question:
Is a drug called, Olezarsen, safe in patients with familial chlyomicronemia syndrome
(FCS)?
Basic Study Information
Purpose:
Familial Chylomicronemia Syndrome (FCS) is a rare genetic disease that causes high
levels of fat in the blood. People with FCS have a high risk of developing pancreatitis,
a serious condition that can lead to death. There is no cure for FCS, but treatment
can help to manage the condition and reduce the risk of complications.
Olezarsen is a new drug that is being developed to treat FCS. It is a type of drug
that can block the production of a protein that helps to carry fat in the blood. By
blocking the production of this protein, Olezarsen can help to lower fat levels in
the blood.
The purpose of the study is to determine if the drug is safe and tolerable in
participants with FCS previously treated with volanesorsen.
Participants will be eligible if they have FCS and are taking or have previously taken
the drug Volanesorsen.
Location: University of Rochester School of Medicine
Study Reference #: STUDY00007228
Lead Researcher (Principal Investigator)
Lead Researcher:
Robert Block
Study Contact Information
Study Coordinator: Ionis Pharmaceuticals
Phone: (844) 583-0450
Email: ionisNCT05130450study@clinicaltrialmedia.com
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search